The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Treating patients with Hodgkin lymphoma who are chemo-resistant
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses treatment strategies for patients with Hodgkin lymphoma (HL) who are resistant to chemotherapy. He mentions cellular therapies and bispecific antibodies, with particular interest in those targeting both PD-1 and TIM-3 immune checkpoints. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
ADC Therapeutics: Research Funding; Pfizer: Research Funding; AstraZeneca: Research Funding; Affimed: Research Funding; Takeda: Research Funding; SeaGen: Research Funding; BMS: Research Funding; Regeneron Pharmaceuticals, Inc.: Research Funding.
